Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dardari, Dured, Thomas, Claire, Laborne, Francois-Xavier, Tourte, Caroline, Henry, Elodie, Erblang, Megane, Bourdon, Stéphanie, Penfornis, Alfred, Lopes, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029471/
https://www.ncbi.nlm.nih.gov/pubmed/35454393
http://dx.doi.org/10.3390/medicina58040555
Descripción
Sumario:The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.

Ejemplares similares